Biocon Biologics in Taiwan
Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing.
It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.
Expanding Access to Lifesaving Therapies in APAC
In the Asia-Pacific (APAC) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 7 commercialized biosimilars.
Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the APAC region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia. The company’s integrated insulins manufacturing and R&D facility in Malaysia, the largest in Asia, manufactures a broad portfolio of regular, basal, and rapid-acting insulins.
Focused on Making a Meaningful Difference in Thailand
In Thailand, Biocon Biologics operates from its office in Bangkok. The company is focused on broadening access to biosimilars for patients and improving healthcare outcomes through its biosimilars for treating cancer, diabetes and autoimmune disease through its five products — Ogivri, a biosimilar to Trastuzumab, used for treating HER2-positive breast cancer and metastatic gastric cancer, Abevmy, a biosimilar to Bevacizumab used in the treatment of various cancers, including colorectal, lung, and kidney cancers, Fulphila, a biosimilar to Pegfilgrastim that helps reduce the risk of infection in patients undergoing chemotherapy, Semglee, a biosimilar to Insulin Glargine used for managing diabetes, and Hulio, a biosimilar to Adalimumab used in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.
Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in Thailand. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in Thailand, making a meaningful impact on patients’ lives.
Commercialized Products
| Sl. No | Brand Name | Molecule Name | THERAPY AREA |
| 1 | Ogivri | Trastuzumab | Cancer |
| 2 | Abevmy | Bevacizumab | Cancer |
| 3 | Fulphila | Pegfilgrastim | Cancer |
| 4 | Semglee | Insulin Glargine | Diabetes |
| 5 | Hulio | Adalimumab | Immunology |
Meet the Leaders
Delivering Highest-Quality Products Globally
80+
03
90+
Our Vision & Values
- Value creation through innovation and differentiation
- Collaboration, teamwork and mutual respect
- Performance-driven work culture
- Quality through compliance and best practices
- Integrity and ethical behaviour
The Biocon Advantage
*19th Annual Report of BioPlan Associates
